LoQus23 bags $43M in Series A to move Huntington's drug into first human study
LoQus23 Therapeutics has secured £35 million ($43 million) in a Series A fundraise led by Forbion and backed by the venture arm of Novartis to help advance its lead Huntington’s disease program into...
View ArticleTriveni to take experimental eczema drug to the clinic, backed by new $115M...
On Wednesday, Triveni Bio became the latest immunology and inflammation startup this year to announce a $100 million-plus financing round. Money has come thick and fast to I&I companies this year,...
View ArticleClik here to view.
Exclusive: After discovering antibiotics with AI, a 31-year-old first-time...
Jim Collins, the famed MIT professor and a godfather of the synthetic biology field, describes Felix Wong as one of the most talented researchers to come out of his lab in recent years. Wong, 31, is...
View ArticleLilly invests $4.5B in new Indiana site to bring clinical manufacturing in-house
Eli Lilly is injecting $4.5 billion into a new manufacturing and drug development factory near its hometown of Indianapolis, in a move aimed at bringing clinical manufacturing in-house and speeding up...
View ArticleClik here to view.
Exclusive: Medicare navigation startup Connie Health is buying a Redesign...
Connie Health, a startup that matches seniors to Medicare plans, bought Redesign Health-backed competitor Keen Insurance Services as insurers step away from selling Medicare plans, driving seniors to...
View ArticleAI company Atomwise's founding CEO exits, casting doubt over startup
Atomwise’s founding CEO Abraham Heifets has left the company after a dozen years, Endpoints News has learned, in the latest challenge for one of the first AI-focused biotech startups. Heifets’ exit was...
View ArticleFrazier adds $630M to public fund to 'take advantage of market volatility'
Frazier Life Sciences has added more than $630 million to its evergreen public fund, the firm said Wednesday. The long-only fund, which is based in Palo Alto, CA, has been marketed to investors as a...
View ArticleWave’s new capital extends cash runway into 2027, CEO says
Wave Life Sciences brought in $230 million through an upsized public offering, extending its cash runway into 2027 as a handful of key programs advance. “It lets everybody breathe,” CEO Paul Bolno said...
View ArticleClik here to view.
Teladoc COO resigns amid executive shuffle
Teladoc’s chief operating officer has resigned due to an executive reshuffle, a few months after the company named a new CEO. Michael Waters COO Michael Waters’ resignation was related to “a change in...
View ArticleA blow to Humana’s Medicare Advantage quality ratings could tank its revenue...
After an already brutal year for its Medicare Advantage business, major health insurer Humana said it’s taken a hit to its health plan quality ratings that threatens to wipe away billions in revenue....
View ArticleJ&J budgets over $2B for new North Carolina biologics facility
Johnson & Johnson is earmarking over $2 billion to build a new biologics manufacturing facility in Wilson, NC, for a variety of therapies for oncology, immunology and neuroscience. Construction of...
View ArticleEMA looks to make its drug approval processes more efficient
The European Medicines Agency is looking to speed up its drug review timelines, following a recent report showing how applications can see long delays. Beginning in 2023, the EMA began monitoring every...
View ArticleGilead licenses HIV shot to six generic manufacturers, but falls short of...
Gilead announced Wednesday that it will allow certain drug manufacturers to make and sell a generic version of its twice-yearly HIV shot lenacapavir in 120 low- and lower-middle income countries. But...
View ArticleAstraZeneca, AbbVie, PhRMA lose court battle over Louisiana 340B law
A Louisiana judge on Monday defended a new state law that keeps drugmakers from imposing certain restrictions around the federal drug discount program known as 340B. The decision marks a loss for...
View ArticleClik here to view.
BioNTech opens the hood on its AI ambitions, and they're not just for mRNA
BioNTech became a big name in biopharma thanks to its Pfizer-partnered Covid-19 vaccine. It’s betting that artificial intelligence will be key to its future. This week, BioNTech and its subsidiary...
View ArticleFor next round of IRA price negotiations, US says it will meet with companies...
The Centers for Medicare & Medicaid Services wants earlier and more flexible communication with drugmakers during the next round of Medicare negotiations, it announced Wednesday. The first round of...
View ArticleSepterna files for Nasdaq listing as biotech IPOs come to life
Septerna is joining biotech’s IPO on-deck circle, preparing for a public offering with two other startups that have recently announced similar plans. It announced its plans in securities filing...
View ArticleResolution raises $85M to test macrophage therapies in end-stage liver disease
By the end of the year, a British biotech plans to start testing a new kind of cell therapy based on macrophages, a roaming immune system sentinel known for gobbling up dead and dying cells throughout...
View ArticleClik here to view.
Investor Kurma Partners raises €140M for latest Europe-focused biotech fund
Kurma Partners has closed the first part of its latest biotech-focused fund, following a pair of M&A exits for drug developers backed by its third fund. Rémi Droller The Paris-based investment firm...
View ArticleEnara Bio’s $32.5M Series B to support lead dark antigen program for GI cancers
Enara Bio has snagged $32.5 million in a Series B fundraise, backed in part by Pfizer’s venture arm, to help develop a preclinical pipeline of T cell receptor-based therapies targeting dark antigens...
View Article